-+ 0.00%
-+ 0.00%
-+ 0.00%

Keybanc Maintains Overweight on Exagen, Lowers Price Target to $10

Benzinga·03/11/2026 13:20:48
Listen to the news
Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and lowers the price target from $15 to $10.